Clinical Trial Update: Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib with bendamustine and rituximab for relapsed/refractory aggressive B-cell lymphomas, with several DLBCL-related conditions in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Diffuse Large B-cell Lymphoma
• Disease
• Mediastinal Large B-cell Lymphoma
• Transformed Indolent Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Meirav Kedmi MD | Conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN